ICCnotes

Inherited Cardiac Conditions reference

Open this condition in the interactive app →

Ehlers-Danlos Syndrome (Vascular Type)

Quick Summary

Definition: An autosomal dominant COL3A1-related connective tissue disorder with fragility and spontaneous rupture of arteries, bowel and gravid uterus.[1]

  • Prevalence: 1 in 50,000-200,000 (MOST LIFE-THREATENING EDS subtype)[1]
  • Key gene: COL3A1 (type III collagen defect), autosomal dominant
  • Hallmark: Arterial/intestinal/uterine rupture + thin translucent skin + easy bruising + characteristic facies
  • High-risk markers: Family history arterial events, pregnancy (uterine rupture risk), ANY arterial dissection/rupture
  • First-line Mx: Celiprolol (reduces vascular events), AVOID invasive procedures, emergency surgery only when essential, genetic counseling

Aetiology

Monogenic (Mendelian): vascular EDS, COL3A1 (rarely COL1A1); ~50% de novo[1]

Genetics

Inheritance: Autosomal dominant; first-degree relatives have a 50% risk of inheriting the pathogenic variant.[1]

Familial vs de novo: Approximately 50% of vEDS cases are familial (inherited from an affected parent); approximately 50% arise as de novo COL3A1 mutations, no prior family history. This high de novo rate means a negative family history does NOT exclude vEDS.[1]

Gene: COL3A1, encodes type III procollagen; structural defect → arterial, uterine, and intestinal fragility

Prevalence

Vascular EDS (vEDS): 1 in 50,000 to 1 in 200,000[1]

Most life-threatening EDS subtype

Diagnosis

Diagnosis is molecular: vascular EDS is confirmed by a pathogenic COL3A1 variant. Clinical suspicion (the criteria below) should trigger urgent genetic testing rather than invasive investigation.[1]

Major criteria:

  • Arterial rupture/dissection
  • Intestinal perforation
  • Uterine rupture (pregnancy)
  • Pneumothorax

Minor features: Thin translucent skin, easy bruising, characteristic facial features, acrogeria (aged appearance of hands)

Investigations

Genetic testing: COL3A1 sequencing (diagnostic; preferred over skin biopsy in the first instance)[1]

Imaging: Vascular imaging ONLY when clinically indicated, significant risk of arterial injury from invasive procedures in COL3A1 disease[2][3]

Treatments

Medical:

  1. Celiprolol: first-line; reduced arterial rupture/dissection in a randomised trial. Up-titrate to the maximum tolerated dose.[4]
  2. Strict blood-pressure control; avoid arterial puncture and elective angiography wherever possible.[3]

Surgery: avoid elective surgery where possible, tissue fragility makes haemostasis and repair difficult; conservative or endovascular management is preferred and should be at a centre familiar with vEDS.[3]

Surveillance: non-invasive arterial imaging (duplex / CT / MR angiography) of the whole arterial tree at individualised intervals.[3]

Practical: patient-held emergency/alert card; plan pregnancy and delivery at an expert centre (high risk of arterial and uterine rupture); avoid contact and high-resistance sports.

Related Resources

Complications

  • Spontaneous arterial rupture or dissection: of medium-sized vessels, often without a preceding aneurysm, and the leading cause of death[1]
  • Hollow-organ rupture: sigmoid colon and gravid uterus, with spontaneous pneumothorax
  • Catastrophic procedural and surgical bleeding: with poor wound healing, so intervention itself is hazardous
  • High peripartum mortality.

Risk Stratification

Median survival: ~50 years

Pregnancy extremely high risk - maternal mortality ~12%

Pregnancy Management

PREGNANCY IN VASCULAR EHLERS-DANLOS SYNDROME - mWHO CLASS IV (ABSOLUTELY CONTRAINDICATED)

MATERNAL MORTALITY RISK: 12-25%

PREGNANCY IS ABSOLUTELY CONTRAINDICATED IN VASCULAR EHLERS-DANLOS SYNDROME

THERE ARE NO SAFE PREGNANCIES IN vEDS

WHY PREGNANCY IS ABSOLUTELY CONTRAINDICATED:

  • Catastrophic maternal outcomes:
    • 12-25% maternal mortality in published case series
    • Death from arterial rupture (60%), uterine rupture (25%), or bowel perforation (15%)
    • Occurs during pregnancy (30%), labour/delivery (40%), or postpartum up to 6 weeks (30%)
    • Rupture is UNPREDICTABLE - occurs without warning, often in previously "normal" vessels
  • Tissue fragility mechanisms:
    • COL3A1 mutation → defective type III collagen → arterial/uterine/bowel wall fragility
    • Pregnancy hormones (relaxin, progesterone) further weaken collagen structure
    • Volume expansion + increased cardiac output → increased wall stress on fragile vessels
    • Uterine expansion stretches already-weak uterine walls
    • Labour = catastrophic risk (contractions, pushing, haemodynamic fluctuations)
  • Sites of rupture (most common):
    • Iliac arteries (most common arterial site)
    • Splenic artery
    • Renal arteries
    • Uterine arteries
    • Uterus itself (spontaneous rupture)
    • Any artery can rupture - unpredictable
  • Cannot be prevented:
    • No prophylactic surgical interventions possible (tissue too fragile for vascular repair)
    • Bed rest, beta-blockers, BP control do NOT eliminate risk
    • Even with optimal monitoring and specialist care: outcomes catastrophic

PRECONCEPTION COUNSELLING - CRITICAL:

  • ALL women with vEDS of childbearing age MUST receive pregnancy counselling:
    • Explain 12-25% maternal mortality risk clearly and unambiguously
    • Emphasize: Rupture is unpredictable, cannot be prevented, often fatal
    • Document counselling extensively (medicolegal protection)
    • STRONGLY ADVISE AGAINST PREGNANCY under any circumstances
  • Alternative family-building options (STRONGLY ENCOURAGE):
    • Gestational surrogacy using patient's eggs: Patient's genetic child without pregnancy risk to patient
    • Adoption: Safe alternative to biological children
    • Child-free life: Valid choice given extreme risks
    • Refer to reproductive medicine specialist + genetic counsellor for options discussion
  • Contraception - ESSENTIAL:
    • LARC (long-acting reversible contraception) MANDATORY for all women of reproductive age:
    • Mirena IUS (levonorgestrel intrauterine system) - preferred (amenorrhoea benefit, 5-year protection)
    • Nexplanon implant (etonogestrel) - alternative (3-year protection)
    • Copper IUD - acceptable if hormonal contraindications
    • Oral contraceptives NOT reliable (user-dependent, pregnancy can still occur)
    • Consider permanent sterilization if family complete (though surgery carries tissue fragility risks - discuss carefully)
    • Male partner vasectomy - safest option (no surgical risk to patient)
  • Genetic counselling:
    • Autosomal dominant: 50% transmission risk to offspring
    • Offspring will have same life-threatening condition
    • Prenatal diagnosis available (CVS, amniocentesis) but pregnancy itself contraindicated
    • Preimplantation genetic diagnosis (PGD) with surrogacy = option for unaffected biological child

IF PREGNANCY OCCURS (unplanned or patient choice despite counselling):

  • Immediate actions:
    • Urgent specialist referral (tertiary centre with vascular surgery, transplant surgery, maternal-fetal medicine, genetics)
    • MDT meeting within 48 hours of diagnosis
    • STRONGLY OFFER TERMINATION OF PREGNANCY given extreme maternal mortality risk
    • Document extensively: counselling, patient decision-making, informed consent regarding mortality risk
    • Involve clinical ethics if patient refuses termination despite counselling
  • If pregnancy continues - management:
    • WEEKLY specialist review throughout pregnancy
    • Baseline CT angiography (head-to-pelvis) - document arterial anatomy for emergency reference
    • Ultrasound surveillance each trimester (assess uterine integrity, fetal growth)
    • NO routine repeat CT/MR (radiation vs benefit; findings don't change management)
    • 24/7 patient access to specialist team (symptoms = emergency)
  • Activity restriction:
    • STRICT bed rest from viability (24 weeks) onwards
    • Some centres recommend bed rest from diagnosis
    • Absolutely no lifting, straining, Valsalva maneuvers, physical exertion
    • Minimize stress (physical and emotional)
  • Medical therapy:
    • Beta-blockers: Labetalol 200-400mg BD (combined alpha/beta blockade, reduces BP and cardiac output)
    • Target BP <110/70 mmHg (lower than standard pregnancy BP targets)
    • No proven pharmacological interventions - beta-blockers are supportive only, NOT protective
  • Patient education - critical symptoms:
    • ANY pain = EMERGENCY: Chest, back, abdominal, pelvic, flank pain
    • Sudden onset severe pain = presumed rupture until proven otherwise
    • Syncope, hypotension, tachycardia = haemorrhage
    • Call ambulance immediately, do NOT delay
    • Inform emergency services: vEDS patient, possible rupture, needs vascular surgery/transplant surgery centre

DELIVERY PLANNING:

  • Timing:
    • Elective delivery at 32 weeks (NO LATER)
    • Rationale: Balance fetal viability vs maternal survival (maternal risk escalates with advancing gestation)
    • Corticosteroids for fetal lung maturity at 31-32 weeks
    • Earlier delivery if symptoms, pain, or clinical concern
  • Location:
    • Tertiary transplant centre with:
    • Vascular surgery and transplant surgery 24/7 (arterial/uterine rupture management)
    • Massive transfusion protocol and blood bank
    • IR (interventional radiology) with embolization capability
    • ICU with ECMO
    • Level 3 NICU (premature infant care)
  • Mode of delivery:
    • Elective caesarean section - ONLY option
    • Vaginal delivery ABSOLUTELY CONTRAINDICATED: Labour contractions, pushing, unpredictable haemodynamics = catastrophic risk
    • Emergency caesarean if spontaneous labour before 32 weeks
  • Surgical considerations:
    • EXTREME tissue fragility: Uterus, blood vessels, fascia all friable
    • Most experienced surgeon available (senior consultant obstetrician + vascular surgeon scrubbed/on standby)
    • Gentle tissue handling, minimal retraction, use of non-absorbable sutures
    • Anticipate difficult haemostasis (vessels tear with manipulation)
    • Consider caesarean hysterectomy at delivery (remove fragile uterus to prevent postpartum rupture) - discuss preoperatively with patient
  • Anaesthesia:
    • Spinal or epidural anaesthesia preferred (avoid general anaesthesia if possible)
    • CRITICAL BP control: Target systolic <100 mmHg intraoperatively
    • Arterial line (beat-to-beat BP monitoring)
    • Large-bore IV access (anticipate massive haemorrhage)
    • Level 1 rapid infuser available
    • Crossmatch 10 units PRBCs minimum
  • Permanent contraception AT DELIVERY:
    • Bilateral tubal ligation or hysterectomy (if performed) at caesarean section
    • Patient MUST NOT have another pregnancy (mortality risk cumulative)
    • Discuss and consent preoperatively
    • Document counselling and consent extensively

POSTPARTUM:

  • EXTENDED high-risk period (6 weeks):
    • 30% of maternal deaths occur postpartum (up to 6 weeks)
    • Uterine involution, hormonal changes, fluid shifts all affect tissue integrity
  • Immediate postpartum (first 7 days):
    • ICU monitoring for minimum 7 days
    • Arterial line for 48-72 hours (continuous BP monitoring)
    • Daily clinical assessment
    • Continue beta-blockers (target BP <120/80 mmHg)
    • Minimize mobilization first 48 hours
  • Outpatient phase (weeks 1-6):
    • WEEKLY specialist review for 6 weeks
    • Patient education: ANY pain = emergency (iliac rupture, uterine rupture, bowel perforation)
    • Home BP monitoring
    • Avoid heavy lifting, straining, Valsalva for 6 weeks
  • Breastfeeding:
    • Generally safe if desired
    • Beta-blockers (labetalol, metoprolol) compatible with breastfeeding
    • Formula feeding acceptable alternative (reduces maternal metabolic demands)
  • Contraception:
    • Should have permanent contraception from caesarean section
    • If not performed: LARC immediately postpartum (Mirena at 6 weeks or Nexplanon before discharge)

IF RUPTURE OCCURS:

  • Arterial rupture:
    • Massive haemorrhage, hypovolaemic shock
    • Emergency laparotomy, vascular control, resuscitation
    • Tissue fragility makes repair extremely difficult - high operative mortality
    • May require damage-control surgery (packing, temporary closure, return to OR)
    • Emergency caesarean delivery if pregnant (if viable gestation)
  • Uterine rupture:
    • Emergency laparotomy, delivery, hysterectomy
    • High maternal and fetal mortality
  • Perimortem caesarean:
    • If maternal cardiac arrest and viable gestation (>24 weeks): deliver within 5 minutes
    • Improves maternal resuscitation outcomes (decompression, increased venous return)
    • Neonatal survival possible if delivered quickly

CRITICAL SUMMARY - VASCULAR EHLERS-DANLOS SYNDROME PREGNANCY:

mWHO Class IV - ABSOLUTELY CONTRAINDICATED
Maternal mortality: 12-25%
THERE ARE NO SAFE PREGNANCIES IN vEDS

Catastrophic arterial/uterine rupture occurs in 12-25% of pregnancies. Rupture is UNPREDICTABLE, cannot be prevented, and is often FATAL. Occurs during pregnancy, labour, or up to 6 weeks postpartum.

ALL WOMEN WITH vEDS MUST BE COUNSELLED AGAINST PREGNANCY.

Alternative family-building options: Surrogacy (using patient's eggs), adoption.

LARC contraception MANDATORY for all women of reproductive age.

If pregnancy occurs: Strongly offer termination. If continues: Deliver at 32 weeks via elective CS at transplant centre, ICU monitoring 7 days, permanent contraception at delivery.

This is the HIGHEST-RISK pregnancy in cardiology/obstetrics.
Patient survival is NOT guaranteed even with optimal care.

Key Points

  • Arterial/bowel rupture can occur spontaneously without warning[1]
  • Avoid invasive vascular procedures when possible (tissue fragility)[1]
  • PREGNANCY mWHO CLASS IV - ABSOLUTELY CONTRAINDICATED (12-25% maternal mortality)[1]
  • Counsel ALL women of childbearing age: surrogacy/adoption strongly preferred over pregnancy
  • If pregnancy occurs: deliver 32 weeks, elective CS, permanent contraception at delivery
  • LARC (Mirena/implant) essential for all women of reproductive age

References & Review Date

Last reviewed: May 2026

  1. Malfait F, et al. The 2017 international classification of the Ehlers-Danlos syndromes. Am J Med Genet C Semin Med Genet. 2017;175(1):8–26. doi:10.1002/ajmg.c.31552
  2. Erbel R, et al. 2014 ESC Guidelines on the diagnosis and treatment of aortic diseases. Eur Heart J. 2014;35(41):2873–2926. doi:10.1093/eurheartj/ehu281
  3. Mazzolai L, Teixido-Tura G, Lanzi S, et al. 2024 ESC Guidelines for the management of peripheral arterial and aortic diseases (incl. vascular Ehlers-Danlos arterial surveillance). Eur Heart J. 2024;45:3538–3700. doi:10.1093/eurheartj/ehae179
  4. Ong KT, Perdu J, De Backer J, et al. Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial. Lancet. 2010;376(9751):1476–1484. doi:10.1016/S0140-6736(10)60960-9